TEVJFライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (19 4月 2024 @ 23:08):

Stats
本日の出来高	4.00
平均出来高	1 847.00
時価総額	13.17B
EPS	$0.0705 ( 2023-09-29 )
Last Dividend	$0.345 ( 2017-06-05 )
Next Dividend	$0 ( N/A )
P/E	-23.50
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Fox Christine	Buy	253 968	Restricted Share Units
2023-11-20	Fox Christine	Buy	0
2023-11-15	Conway Vikki L	Buy	33 482	Restricted Share Units
2023-11-15	Bergwerk Dov	Buy	33 482	Restricted Share Units
2023-10-13	Bergwerk Dov	Sell	0	Ordinary Shares

INSIDER POWER
23.25
Last 96 transactions
Buy: 1 572 847 \| Sell: 982 807

Teva Pharmaceutical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Teva Pharmaceutical 財務諸表

Annual	2023
収益:	$15.85B
総利益:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2023
収益:	$15.85B
総利益:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2022
収益:	$14.93B
総利益:	$6.97B (46.72 %)
EPS:	$-2.19

FY	2021
収益:	$15.88B
総利益:	$7.60B (47.83 %)
EPS:	$0.380

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.52 - low (50.11%) | Divividend Growth Potential Score: 0.653 - No dividend growth expected in the near future

Information

First Dividend	$0.346	2014-02-24
Last Dividend	$0.345	2017-06-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	7	--
Total Paid Out	$2.38	--
Avg. Dividend % Per Year	0.00%	--
Score	1.85	--
Div. Sustainability Score	4.52
Div.Growth Potential Score	0.653
Div. Directional Score	2.59	--

Next Divdend (Est)
(2024-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
TYFG	Ex Dividend Junior	2023-09-28	Quarterly	0.00%
JRONY	Ex Dividend Knight	2023-05-15	Annually	0.00%
BPOSY	Ex Dividend Knight	2023-05-18	Annually	0.00%
RMYHY	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
FCELB	Ex Dividend Junior	2023-07-31	Semi-Annually	0.00%
VWAPY	Ex Dividend Junior	2023-05-11	Annually	0.00%
LRENY	Ex Dividend Knight	2023-06-30	Quarterly	0.00%
CKNQP	Ex Dividend Junior	2023-09-14	Quarterly	0.00%
SKHHY	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
GTPS	Ex Dividend Knight	2023-09-14	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0374	1.500	-0.748	-1.123	[0 - 0.5]
returnOnAssetsTTM	-0.0136	1.200	-0.455	-0.546	[0 - 0.3]
returnOnEquityTTM	-0.0808	1.500	-2.01	-3.01	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.019	0.800	9.90	7.92	[1 - 3]
quickRatioTTM	0.542	0.800	-1.520	-1.216	[0.8 - 2.5]
cashRatioTTM	0.263	1.500	9.65	10.00	[0.2 - 2]
debtRatioTTM	0.464	-1.500	2.27	-3.41	[0 - 0.6]
interestCoverageTTM	0.914	1.000	-0.773	-0.773	[3 - 30]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.751	2.00	9.62	10.00	[0 - 20]
debtEquityRatioTTM	2.68	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0593	1.000	-0.814	-0.814	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0679	1.000	-0.734	-0.734	[0.2 - 2]
assetTurnoverTTM	0.364	0.800	-0.904	-0.723	[0.5 - 2]
Total Score				4.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-22.21	1.000	-2.34	0	[1 - 100]
returnOnEquityTTM	-0.0808	2.50	-1.292	-3.01	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.751	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.256	1.500	-5.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				0.653

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.